DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,132,087 B2 Lichter Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,132,087 B2 Lichter Et Al US009132087B2 (12) United States Patent (10) Patent No.: US 9,132,087 B2 Lichter et al. (45) Date of Patent: Sep. 15, 2015 (54) AURIS FORMULATIONS FOR TREATING (52) U.S. Cl. OTC DISEASES AND CONDITIONS CPC ................. A61 K9/0046 (2013.01); A61 K9/06 (2013.01); A61K 9/14 (2013.01) (75) Inventors: Jay Lichter, Rancho Santa Fe, CA (US); (58) Field of Classification Search Andrew M. Trammel, Olathe, KS (US); Fabrice Piu, San Diego, CA (US); Luis CPC .......... A61 K9/0046; A61 K9/06; A61 K9/14 A. Dellamary, San Marcos, CA (US); See application file for complete search history. Qiang Ye, San Diego, CA (US); Carl (56) References Cited Lebel, Malibu, CA (US); Michael Christopher Scaife, Los Altos, CA U.S. PATENT DOCUMENTS (US); Jeffrey P. Harris, La Jolla, CA 4,478,822 A 10, 1984 Haslam et al. (US) 4,530,840 A 7, 1985 Tice et al. 4,900,552 A 2f1990 Sanvordeker et al. (73) Assignees: OTONOMY, INC., San Diego, CA 4,938,763. A 7, 1990 Dunn et al. 4,968,507 A * 1 1/1990 Zentner et al. ................ 424/465 (US): THE REGENTS OF THE 5,292,516 A 3/1994 Viegas et al. UNIVERSITY OF CALIFORNLA, 5,324,519 A 6/1994 Dunn et al. Oakland, CA (US) 5,451,399 A 9/1995 Gimbrone, Jr. et al. 5,503,848 A 4/1996 Perbellini et al. (*) Notice: Subject to any disclaimer, the term of this 5,702,716 A 12/1997 Dunn et al. patent is extended or adjusted under 35 5,714,167 A 2f1998 Milstein et al. 5,744, 153 A 4/1998 Yewey et al. U.S.C. 154(b) by 477 days. 5,814,330 A 9, 1998 Putteman et al. 5,985,848 A 11/1999 Furneaux et al. (21) Appl. No.: 12/427,663 5.990, 194 A 11/1999 Dunn et al. 6,004,543 A 12/1999 Galey (22) Filed: Apr. 21, 2009 6,066,722 A 5, 2000 Furneaux et al. 6,117,949 A 9, 2000 Rathi et al. Prior Publication Data 6,139,870 A 10/2000 Verrecchia (65) 6,177,434 B1 1/2001 Kopke et al. US 2009/0306225A1 Dec. 10, 2009 (Continued) FOREIGN PATENT DOCUMENTS Related U.S. Application Data EP 1107791 B1 5/2007 (60) Provisional application No. 61/087,905, filed on Aug. WO WO95.04533 A2 * 2, 1995 11, 2008, provisional application No. 61/055,625, filed on May 23, 2008, provisional application No. (Continued) 61/086,105, filed on Aug. 4, 2008, provisional OTHER PUBLICATIONS application No. 61/073,716, filed on Jun. 18, 2008, provisional application No. 61/140,033, filed on Dec. Hallet. al., Antimicrobial Agents & Chemotherapy, 1998, American 22, 2008, provisional application No. 61/127,713, Society for Microbiology, vol. 42, No. 4, pp. 666-674.* filed on May 14, 2008, provisional application No. Wang et al., Otology and Neurotology, 2003, Lippincott Williams and Wilkins, vol. 24, pp. 52-57.* 61/101,112, filed on Sep. 29, 2008, provisional Karolewicz and Pluta, “Thermosensitive polymers in drug form tech application No. 61/094,384, filed on Sep. 4, 2008, nology II. Possibilities of use of thermosensitive polymers as active provisional application No. 61/074,583, filed on Jun. Substance carriers.” Polimery W Medycynie 38(1): 15-26, 2008 20, 2008, provisional application No. 61/060,425, (English language abstract). filed on Jun. 10, 2008, provisional application No. PCT/US2009/041320 International Search Report mailed Nov. 26, 61/048.878, filed on Apr. 29, 2008, provisional 2009. application No. 61/046,543, filed on Apr. 21, 2008, (Continued) provisional application No. 61/076,567, filed on Jun. 27, 2008, provisional application No. 61/076,576, Primary Examiner — Sarah Pihonak filed on Jun. 27, 2008, provisional application No. (74) Attorney, Agent, or Firm — Wilson Sonsini Goodrich & 61/160,233, filed on Mar. 13, 2009, provisional Rosati application No. 61/086,094, filed on Aug. 4, 2008, provisional application No. 61/083,830, filed on Jul. (57) ABSTRACT 25, 2008, provisional application No. 61/083,871, Disclosed herein are compositions and methods for the treat filed on Jul. 25, 2008, provisional application No. ment of otic disorders with immunomodulating agents and 61/087,951, filed on Aug. 11, 2008, provisional auris pressure modulators. In these methods, the auris com application No. 61/088,275, filed on Aug. 12, 2008, positions and formulations are administered locally to an provisional application No. 61/082,450, filed on Jul. individual afflicted with anotic disorder, through direct appli 21, 2008. cation of the immunomodulating and/or auris pressure modu lating compositions and formulations onto the auris media (51) Int. C. and/or auris internatarget areas, or via perfusion into the auris A6 IK9/00 (2006.01) media and/or auris interna structures. A6 IK9/06 (2006.01) A6 IK 9/14 (2006.01) 6 Claims, 4 Drawing Sheets US 9,132,087 B2 Page 2 (56) References Cited 2007/0281978 A1 12/2007 Nakada et al. 2007,02991 13 A1 12/2007 Kalvinsh et al. U.S. PATENT DOCUMENTS 2008.00151.83 A1 1/2008 Bakthavatchalam et al. 2008/0085901 A1 4/2008 Caldwell et al. 6,201,072 B1 3, 2001 Rathi et al. 2008, OO88713 A1 4/2008 Jung et al. 6,221,367 B1 4, 2001 Milstein et al. 2008.0089883 A1 4/2008 Kandimalla et al. 6,228,847 B1 5, 2001 Furneaux et al. 2008. O103118 A1 5/2008 Clement et al. 6,287,588 B1 9, 2001 Shih et al. 2008. O153857 A1 6/2008 Bakthavatchalam et al. 6,306,789 B1 10, 2001 Dettmar et al. 2008/O175794 A1 7/2008 Caldwell et al. 6,316,011 B1 11, 2001 Ron et al. 2011 0166060 A1 7/2011 Simons et al. 6,319,513 B1 11, 2001 Dobrozki 6,348,502 B1 2, 2002 Gardiner et al. FOREIGN PATENT DOCUMENTS 6,392,036 B1 5, 2002 Karlsson et al. 6,492,347 B2 12, 2002 Furneaux et al. WO WO97/38698 10, 1997 6,509,028 B2 1, 2003 Williams et al. WO WO-99/O1441 1, 1999 6,548,527 B2 4, 2003 Rahman WO WO99,24051 5, 1999 6,562,363 B1 5/2003 Mantelle et al. WO WO-99/24051 5, 1999 6,589,549 B2 T/2003 Shih et al. WO WO-01/00610 1, 2001 6,638,521 B2 10, 2003 Dobrozki WO WO-01/30774 5, 2001 6,649,621 B2 11, 2003 Kopke et al. WO WO-O 1/58890 8, 2001 6,740,664 B2 5, 2004 Cagle et al. WO WO-01 68648 9, 2001 6,803455 B2 10, 2004 Furneaux et al. WO WO-O2,246.79 3, 2002 7,001,615 B1 2, 2006 Singh et al. WO WO-O2,30353 4/2002 7,018,645 B1 3, 2006 Piao et al. WO WO-02/30423 4/2002 7,151,191 B2 12, 2006 Boyd et al. WO WO-02/41843 5, 2002 7,279,499 B2 10, 2007 Durst et al. WO WO-02? 44153 6, 2002 7,524,834 B2 4, 2009 Karlsson et al. WO WO-O2/46171 6, 2002 7,589,110 B2 9, 2009 Puel et al. WO WO-02-056890 A1 T 2002 8,030,297 B2 10, 2011 Lichter et al. WO WO-02/060386 8, 2002 8, 197461 B1 6, 2012 Arenberg WO WO-O2/O94265 11, 2002 8,648,119 B2 2, 2014 Lichter et al. WO WO-O2/O94322 11, 2002 2001 OO19823 A1 9, 2001 Schramm et al. WO WO-03/010163 2, 2003 2002fOO44920 A1 4, 2002 Rahman et al. .............. 424,85.1 WO WOO3,O17990 3, 2003 2002fOO61898 A1 5, 2002 Furneaux et al. WO WO-O3,O24935 3, 2003 2002/0132783 A1 9, 2002 Sauve et al. WO WO-O3,O24936 3, 2003 2003/0092776 A1 5/2003 Ron et al. WO WO-O3,O29242 4/2003 2003/0096830 A1 5, 2003 Furneaux et al. WO WO 2003/034979 5, 2003 2003/0129240 A1 T/2003 Reeve et al. WO WO-O3,O76447 9, 2003 2003. O1492.61 A1 8, 2003 Schramm et al. WO WO 2003/071986 9, 2003 2003/0229.333 A1 12, 2003 Ashton WO WO-2004/058754 T 2004 2004.0053944 A1 3, 2004 Furneaux et al. WO WO-2005.009987 2, 2005 2004/OO82509 A1 4, 2004 Bonny WO WO-2005,113544 12/2005 2004/0101560 A1 5, 2004 Sawchuk et al. WO WO-2006/076318 T 2006 2004/O110772 A1 6, 2004 Furneaux et al. WO WO 2006/099325 9, 2006 2004/O181063 A1 9, 2004 Furneaux et al. WO WO 2007/031098 3, 2007 2004/O185047 A1 9, 2004 Giles-Komar et al. WO WO 2007/031280 3, 2007 2004/O192763 A1 9, 2004 Chenard et al. WO WO 2007/037874 4/2007 2004/O247575 A1 12, 2004 Caplice et al. WO WO 2007/037886 4/2007 2005/O123541 A1 6, 2005 Heavner et al. WO WO 2007/038949 4/2007 2005, 0147585 A1 7/2005 Schwarz WO WO-2007-045876 A1 4/2007 2005/O153984 A1 7/2005 Chen et al. WO WO-2007 150016 12/2007 2005/0214.338 A1 9, 2005 Guitton et al. WO WO 2008/076.556 6, 2008 2005/0215572 A1 9, 2005 Kelly et al. WO WO-2010-048.095 A2 4/2010 2005/0227986 A1 10, 2005 Bo et al. WO WO-2010-048.095 A3 4/2010 2005/0272931 A1 12, 2005 Bo et al. 2005/0277631 A1 12, 2005 Doherty et al.
Load more

Recommended publications
  • Press Release
    Ménière's Society for dizziness and balance disorders NEWS RELEASE Release date: Monday 17 September 2018 Getting help if your world is in a spin Feeling dizzy and losing your balance is an all too common problem for many people but would you know what to do and where to get help if this happened to you? A loss of balance can lead to falls whatever your age. Around 30% of people under the age of 65 suffer from falls with one in ten people of working age seeking medical advice for vertigo which can lead to life changing or life inhibiting symptoms. Balance disorders are notoriously difficult to diagnose accurately. Most people who feel giddy, dizzy, light-headed, woozy, off-balance, faint or fuzzy, have some kind of balance disorder. This week (16-22 September 2018) is Balance Awareness Week. Organised by the Ménière's Society, the only registered charity in the UK dedicated solely to supporting people with inner ear disorders, events up and down the country will aim to raise awareness of how dizziness and balance problems can affect people and direct them to sources where they can find support. This year Balance Awareness Week also sees the launch of the world’s first Balance Disorder Spectrum, enabling for the first time easy reference to the whole range of balance disorders in one easy to use interactive web site. Medical science is continuously updating and revising its understanding of these often distressing and debilitating conditions. The many different symptoms and causes of balance disorders mean that there have been few attempts to show what they have in common, until now.
    [Show full text]
  • How Do I Know If I Have a Balance Disorder?
    PO BOX 13305 · PORTLAND, OR 97213 · FAX: (503) 229-8064 · (800) 837-8428 · [email protected] · WWW.VESTIBULAR.ORG How Do I Know if I Have a Balance Disorder? This article is adapted from information provided by the National Institute on Deafness and Other Communications Disorders, (NIDCD). Millions of individuals have disorders of sensation of spatial disorientation or balance they describe as “dizziness.” imbalance. Experts believe that more than four out of ten Americans will experience an Almost everyone experiences a few episode of dizziness significant enough to seconds of dizziness or disequilibrium at send them to a doctor. some point —for example, when a person stands on a train platform and What can be difficult for both a patient momentarily perceives an illusion of and his or her doctor is that the word moving as a train rushes past. However, “dizziness” is a subjective term. This for some people, symptoms can be means that the word can be used by intense and last a long time, affecting a people to describe different sensations person’s independence, ability to work, they are experiencing, but it is hard for and quality of life. anyone but the person experiencing the symptoms to understand or measure Balance disorders can be caused by the nature or severity of the sensations. medications or certain health conditions, In addition, people tend to use different including problems with the inner ear terms to describe the same kind of (vestibular) organs or the brain. problem. “Dizziness,” “vertigo,” and Dizziness, vertigo, and disequilibrium are “disequilibrium” are often used all symptoms that can result from a interchangeably, even though they have peripheral vestibular disorder (a different meanings.
    [Show full text]
  • Balance Disorder Spectrum Technical Report: January 2018
    Balance Disorder Spectrum Technical Report: January 2018 Professor Andrew Hugill Professor Peter Rea College of Science and Engineering The Leicester Balance Centre University of Leicester Department of ENT Leicester, UK Leicester Royal Infirmary [email protected] Leicester, UK Abstract—This paper outlines the technical aspects of the first version of a new spectrum of balance disorders. It describes the II. BALANCE DISORDER SPECTRUM implementation of the spectrum in an interactive web page and proposes some avenues for future research and development. A. Rationale Balance disorders are often both unclear and difficult to Keywords—balance, disorder, spectrum diagnose, so the notion of a spectrum may well prove useful as an introduction to the field. Thanks to existing spectrums (e.g. I. INTRODUCTION autism), the general public is now familiar with the idea of a This project seeks to create an interactive diagnostic tool collection of related disorders ranging across a field that might for the identification of balance disorders, to be used by be anything from mild to severe. The importance of balance clnicians and GPs as well as the wider public. There are three disorders is generally underestimated. The field has suffered main layers to the project: from a fragmented nomenclature and conflicting medical opinions, resulting from a general uncertainty and even • the establishment of the concept of a spectrum of confusion about both symptoms and causes. Terms such as: balance disorders; dizzy, light-headed, floating, woozy, giddy, off-balance, • the creation of an interactive web page providing feeling faint, helpless, or fuzzy, are used loosely and access to the spectrum and its underlying medical interchangeably, consolidating the impression that this is a information; vague collection of ailments.
    [Show full text]
  • Mal De Debarquement Syndrome (Mdds)?
    What is Mal de Debarquement Syndrome (MdDS)? MdDS is a rare and life-altering balance disorder that most commonly develops after an ocean cruise or other type of water travel. MdDS is also known as disembarkment disease or persistent landsickness. MdDS also occurs following air/train travel or other motion experiences or spontaneously/in the absence of a motion event. MdDS is a syndrome because it often includes a diverse array of symptoms. The characteristic symptom of MdDS is a persistent sensation of motion such as rocking, swaying and/or bobbing. Other MdDS Symptoms: MAL de • Disequilibrium - a sensation of unsteadiness DEBARQUEMENT or loss of balance • Fatigue; extreme, unusual SYNDROME • Cognitive impairment - difficulty concentrating, confusion, memory loss …a persistent • Anxiety, depression motion and imbalance disorder… • Ataxia – unsteady, staggering gait • Sensitivity to flickering lights, loud or sudden noises, fast or sudden movements, enclosed areas or busy patterns Do you know a person who has • Headaches, including migraine headaches • Heaviness - sensation of gravitational pull of returned from an ocean cruise and the head, body or feet feels like they are still on the boat – • Dizziness months/years later? • Ear pain and/or fullness • Tinnitus – ringing in the ears Perhaps they returned from a • Nausea plane, train or lengthy car ride, and Most MdDS patients feel relief while driving/ it now feels like they are on a ship riding in an auto, airplane, train or other at sea. motion activities. However, the abnormal sensation of motion returns as soon as the They may be suffering from Mal de motion activity is suspended. This is a Debarquement Syndrome (MdDS), helpful feature in the diagnosis of MdDS.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Bedside Neuro-Otological Examination and Interpretation of Commonly
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2004.054478 on 24 November 2004. Downloaded from BEDSIDE NEURO-OTOLOGICAL EXAMINATION AND INTERPRETATION iv32 OF COMMONLY USED INVESTIGATIONS RDavies J Neurol Neurosurg Psychiatry 2004;75(Suppl IV):iv32–iv44. doi: 10.1136/jnnp.2004.054478 he assessment of the patient with a neuro-otological problem is not a complex task if approached in a logical manner. It is best addressed by taking a comprehensive history, by a Tphysical examination that is directed towards detecting abnormalities of eye movements and abnormalities of gait, and also towards identifying any associated otological or neurological problems. This examination needs to be mindful of the factors that can compromise the value of the signs elicited, and the range of investigative techniques available. The majority of patients that present with neuro-otological symptoms do not have a space occupying lesion and the over reliance on imaging techniques is likely to miss more common conditions, such as benign paroxysmal positional vertigo (BPPV), or the failure to compensate following an acute unilateral labyrinthine event. The role of the neuro-otologist is to identify the site of the lesion, gather information that may lead to an aetiological diagnosis, and from there, to formulate a management plan. c BACKGROUND Balance is maintained through the integration at the brainstem level of information from the vestibular end organs, and the visual and proprioceptive sensory modalities. This processing takes place in the vestibular nuclei, with modulating influences from higher centres including the cerebellum, the extrapyramidal system, the cerebral cortex, and the contiguous reticular formation (fig 1).
    [Show full text]
  • Confirmed Otosclerosis
    Biomedical Research and Therapy, 6(3):3034-3039 Original Research Evaluation of balance function in patients with radiologically (CT scan) confirmed otosclerosis Rania Abdulfattah Sharaf1;∗, Rudrapathy Palaniappan2 ABSTRACT Objective: To assess balance function in patients with radiologically confirmed otosclerosis. Meth- ods: Sixteen patients (14 females and 2 males), who attended the Neuro-Otology clinic/ ENT clinics at the Royal National Throat Nose and Ear Hospital, participated in this study. After general medical, audiological and Neuro-Otological examination, patients underwent the caloric and rotational test- ing. Results: Thirteen of the 16 patients had radiologically confirmed otosclerosis (12 females and 1 male). A total of 3 patients (2 females and 1 male) did not have CT confirmation of otosclerosis, and therefore, were excluded from the study. The remaining 13 patients' data were analyzed. Nine patients had a mixed hearing impairment at least on one side, while eight patients had a bilateral mixed hearing loss and one patient had a sensorineural hearing loss on one side. Four patients had a bilateral sensorineural hearing loss. Only 1 patient had a canal paresis (CP) at 35 %. None of the patients had any significant directional preponderance (DP). The patient with significant CP (35%) did not show any rotational asymmetry on impulsive rotation. Eleven patients had a rotational chair test. Only one patient had a significant asymmetry to the right at 25.30% (normal range is <20%). Overall, 18% (n = 2) of the radiologically confirmed otosclerosis patients showed an abnormal bal- ance test, including both caloric and rotational tests. More than 80% (n = 9) of the patients with radiological otosclerosis showed balance symptoms.
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T (51) International Patent Classification: (74) Agents: CHOTIA, Meenakshi et al; K&S Partners | Intel A 25/12 (2006.01) A61K 8/11 (2006.01) lectual Property Attorneys, 4121/B, 6th Cross, 19A Main, A 25/34 (2006.01) A61K 8/49 (2006.01) HAL II Stage (Extension), Bangalore 560038 (IN). A01N 37/06 (2006.01) A61Q 5/00 (2006.01) (81) Designated States (unless otherwise indicated, for every A O 43/12 (2006.01) A61K 31/44 (2006.01) kind of national protection available): AE, AG, AL, AM, AO 43/40 (2006.01) A61Q 19/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A01N 57/12 (2006.01) A61K 9/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, AOm 59/16 (2006.01) A61K 31/496 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/IB20 14/06 1925 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 3 June 2014 (03.06.2014) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • General Agreement on Tariffs Andtrade
    RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code
    [Show full text]
  • Is There a Link Between Usher Syndrome Type II and Balance Problems Or Vertigo?
    Is there a link between Usher syndrome type II and balance problems or vertigo? Information Monitoring Summary Documentary research Josée Duquette, Planning, Programming and Research Officer Francine Baril, Documentation Technician Prepared by Josée Duquette, Planning, Programming and Research Officer October 21st, 2009 Notice to readers The information in the following pages is not intended to be an exhaustive review of the literature. The goal was to make directly relevant selected information more readily available. Accordingly, not all articles or documents dealing with the topic have been reviewed. Authorization to reproduce This document and the accompanying material may be reproduced for clinical, teaching or research purposes with the prior written consent of l’Institut Nazareth et Louis-Braille. Modifying this document and the accompanying material in any way whatsoever is strictly prohibited. Any reproduction in whole or in part of this document and the accompanying material for commercial purposes is strictly prohibited. © Institut Nazareth et Louis-Braille, 2009 SUMMARY Usher syndrome type II is characterized by moderate to severe congenital deafness, normal vestibular function, and retinitis pigmentosa usually appearing in the patient’s late twenties or early thirties. Clinicians in the deaf-blindness program run jointly by the Institut Nazareth et Louis-Braille and the Institut Raymond-Dewar have noticed that certain patients with this form of the syndrome complain of vertigo, dizziness and loss of balance. The literature confirms that there are atypical forms of Usher syndrome type II characterized by, among others, vestibular dysfunction [1-3]. Other cases have also been reported in the scientific literature or anecdotally [7; 8].
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]